Not all next generation sequencing diagnostics are created equal: Understanding the nuances of solid tumor assay design for somatic mutation detection

Cancers

Volumn 7, Issue 3, 2015, Pages 1313-1332

  Gray, Phillip N ^a   Dunlop, Charles L M ^a   Elliott, Aaron M ^a  

^a AMBRY GENETICS   (United States)

Author keywords

Cancer panels; Copy number; Germline; Molecular inversion probes; Next generation sequencing; Somatic; Target enrichment

Indexed keywords

BIOINFORMATICS; COPY NUMBER VARIATION; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GERMLINE MUTATION; HUMAN; KARYOTYPING; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; SOMATIC MUTATION;

EID: 84937412447     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7030837     Document Type: Review

References (84)

1. Igbokwe, A.; Lopez-Terrada, D. H. Molecular testing of solid tumors. Arch. Pathol. Lab. Med. 2011, 135, 67-82. [PubMed].
2. McCourt, C. M.; Boyle, D.; James, J.; Salto-Tellez, M. Immunohistochemistry in the era of personalised medicine. J. Clin. Pathol. 2013, 66, 58-61. [CrossRef] [PubMed].
3. Pauletti, G.; Dandekar, S.; Rong, H.; Ramos, L.; Peng, H.; Seshadri, R.; Slamon, D. J. Assessment of methods for tissue-based detection of the her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 2000, 18, 3651-3664. [PubMed].
4. Lebeau, A.; Deimling, D.; Kaltz, C.; Sendelhofert, A.; Iff, A.; Luthardt, B.; Untch, M.; Lohrs, U. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 2001, 19, 354-363. [PubMed].
5. Angulo, B.; Garcia-Garcia, E.; Martinez, R.; Suarez-Gauthier, A.; Conde, E.; Hidalgo, M.; Lopez-Rios, F. A commercial real-time pcr kit provides greater sensitivity than direct sequencing to detect kras mutations: A morphology-based approach in colorectal carcinoma. J. Mol. Diagn. 2010, 12, 292-299. [CrossRef] [PubMed].
6. Gonzalez de Castro, D.; Angulo, B.; Gomez, B.; Mair, D.; Martinez, R.; Suarez-Gauthier, A.; Shieh, F.; Velez, M.; Brophy, V. H.; Lawrence, H. J.; et al. A comparison of three methods for detecting kras mutations in formalin-fixed colorectal cancer specimens. Br. J. Cancer 2012, 107, 345-351. [CrossRef] [PubMed].
7. Lopez-Rios, F.; Angulo, B.; Gomez, B.; Mair, D.; Martinez, R.; Conde, E.; Shieh, F.; Vaks, J.; Langland, R.; Lawrence, H. J.; et al. Comparison of testing methods for the detection of braf v600e mutations in malignant melanoma: Pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS ONE 2013, 8, e53733. [CrossRef] [PubMed].
8. Solin, L. J.; Gray, R.; Baehner, F. L.; Butler, S. M.; Hughes, L. L.; Yoshizawa, C.; Cherbavaz, D. B.; Shak, S.; Page, D. L.; Sledge, G. W., Jr.; et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 2013, 105, 701-710. [CrossRef] [PubMed].
9. Cobas 4800 braf v600 mutation test. Available online: http://molecular. roche. com/assays/Pages/cobas4800BRAFV600MutationTest. aspx (accessed on 15 May 2015).
10. Cobas egfr mutation test. Available online: http://molecular. roche. com/assays/Pages/cobasEGFRMutationTest. aspx (accessed on 15 May 2015).
11. Lambros, M. B.; Natrajan, R.; Reis-Filho, J. S. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum. Pathol. 2007, 38, 1105-1122. [CrossRef] [PubMed].
12. Gruver, A. M.; Peerwani, Z.; Tubbs, R. R. Out of the darkness and into the light: Bright field in situ hybridisation for delineation of erbb2 (her2) status in breast carcinoma. J. Clin. Pathol. 2010, 63, 210-219. [CrossRef] [PubMed].
13. Korbel, J. O.; Urban, A. E.; Affourtit, J. P.; Godwin, B.; Grubert, F.; Simons, J. F.; Kim, P. M.; Palejev, D.; Carriero, N. J.; Du, L.; et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 2007, 318, 420-426. [CrossRef] [PubMed].
14. Pleasance, E. D.; Cheetham, R. K.; Stephens, P. J.; McBride, D. J.; Humphray, S. J.; Greenman, C. D.; Varela, I.; Lin, M. L.; Ordonez, G. R.; Bignell, G. R.; et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463, 191-196. [CrossRef] [PubMed].
15. Chen, K.; Wallis, J. W.; McLellan, M. D.; Larson, D. E.; Kalicki, J. M.; Pohl, C. S.; McGrath, S. D.; Wendl, M. C.; Zhang, Q.; Locke, D. P.; et al. Breakdancer: An algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 2009, 6, 677-681. [CrossRef] [PubMed].
16. Chiang, D. Y.; Getz, G.; Jaffe, D. B.; O'Kelly, M. J.; Zhao, X.; Carter, S. L.; Russ, C.; Nusbaum, C.; Meyerson, M.; Lander, E. S. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Methods 2009, 6, 99-103. [CrossRef] [PubMed].
17. Wagle, N.; Berger, M. F.; Davis, M. J.; Blumenstiel, B.; Defelice, M.; Pochanard, P.; Ducar, M.; van Hummelen, P.; Macconaill, L. E.; Hahn, W. C.; et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2011, 2, 82-93. [CrossRef] [PubMed].
18. Frampton, G. M.; Fichtenholtz, A.; Otto, G. A.; Wang, K.; Downing, S. R.; He, J.; Schnall-Levin, M.; White, J.; Sanford, E. M.; An, P.; et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31, 1023-1031. [CrossRef] [PubMed].
19. Cottrell, C. E.; Al-Kateb, H.; Bredemeyer, A. J.; Duncavage, E. J.; Spencer, D. H.; Abel, H. J.; Lockwood, C. M.; Hagemann, I. S.; O'Guin, S. M.; Burcea, L. C.; et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J. Mol. Diagn. 2014, 16, 89-105. [CrossRef] [PubMed].
20. Pritchard, C. C.; Salipante, S. J.; Koehler, K.; Smith, C.; Scroggins, S.; Wood, B.; Wu, D.; Lee, M. K.; Dintzis, S.; Adey, A.; et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 2014, 16, 56-67. [CrossRef] [PubMed].
21. "Next generation" sequencing (ngs) guidelines for somatic genetic variant detection. Available online: http://www. wadsworth. org/labcert/TestApproval/forms/NextGenSeq_ONCO_Guidelines. pdf (accessed on 15 May 2015).
22. Mamanova, L.; Coffey, A. J.; Scott, C. E.; Kozarewa, I.; Turner, E. H.; Kumar, A.; Howard, E.; Shendure, J.; Turner, D. J. Target-enrichment strategies for next-generation sequencing. Nat. Methods 2010, 7, 111-118. [CrossRef] [PubMed].
23. Drilon, A.; Wang, L.; Arcila, M. E.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; Kris, M. G.; et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin. Cancer Res. 2015. [CrossRef] [PubMed].
24. Ikegawa, S.; Mabuchi, A.; Ogawa, M.; Ikeda, T. Allele-specific pcr amplification due to sequence identity between a pcr primer and an amplicon: Is direct sequencing so reliable? Hum. Genet. 2002, 110, 606-608. [CrossRef] [PubMed].
25. Hahn, S.; Garvin, A. M.; Di Naro, E.; Holzgreve, W. Allele drop-out can occur in alleles differing by a single nucleotide and is not alleviated by preamplification or minor template increments. Genet. Test 1998, 2, 351-355. [CrossRef] [PubMed].
26. Barnard, R.; Futo, V.; Pecheniuk, N.; Slattery, M.; Walsh, T. Pcr bias toward the wild-type k-ras and p53 sequences: Implications for pcr detection of mutations and cancer diagnosis. BioTechniques 1998, 25, 684-691. [PubMed].
27. Chong, H. K.; Wang, T.; Lu, H. M.; Seidler, S.; Lu, H.; Keiles, S.; Chao, E. C.; Stuenkel, A. J.; Li, X.; Elliott, A. M. The validation and clinical implementation of brcaplus: A comprehensive high-risk breast cancer diagnostic assay. PLoS ONE 2014, 9, e97408. [CrossRef] [PubMed].
28. Kozarewa, I.; Ning, Z.; Quail, M. A.; Sanders, M. J.; Berriman, M.; Turner, D. J. Amplification-free illumina sequencing-library preparation facilitates improved mapping and assembly of (g+c)-biased genomes. Nat. Methods 2009, 6, 291-295. [CrossRef] [PubMed].
29. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R. The sequence alignment/map format and samtools. Bioinformatics 2009, 25, 2078-2079. [CrossRef] [PubMed].
30. Pireddu, L.; Leo, S.; Zanetti, G. Seal: A distributed short read mapping and duplicate removal tool. Bioinformatics 2011, 27, 2159-2160. [CrossRef] [PubMed].
31. Picard. Available online: http://broadinstitute. github. io/picard/(accessed on 15 May 2015).
32. Smith, E. N.; Jepsen, K.; Khosroheidari, M.; Rassenti, L. Z.; D'Antonio, M.; Ghia, E. M.; Carson, D. A.; Jamieson, C. H.; Kipps, T. J.; Frazer, K. A. Biased estimates of clonal evolution and subclonal heterogeneity can arise from pcr duplicates in deep sequencing experiments. Genome Biol. 2014, 15. [CrossRef] [PubMed].
33. Kanagawa, T. Bias and artifacts in multitemplate polymerase chain reactions (pcr). J. Biosci. Bioeng. 2003, 96, 317-323. [CrossRef].
34. Rait, V. K.; Zhang, Q.; Fabris, D.; Mason, J. T.; O'Leary, T. J. Conversions of formaldehyde-modified 2'-deoxyadenosine 5'-monophosphate in conditions modeling formalin-fixed tissue dehydration. J. Histochem. Cytochem. 2006, 54, 301-310. [CrossRef] [PubMed].
35. Miner, B. E.; Stoger, R. J.; Burden, A. F.; Laird, C. D.; Hansen, R. S. Molecular barcodes detect redundancy and contamination in hairpin-bisulfite pcr. Nucleic Acids Res. 2004, 32, e135. [CrossRef] [PubMed].
36. Casbon, J. A.; Osborne, R. J.; Brenner, S.; Lichtenstein, C. P. A method for counting pcr template molecules with application to next-generation sequencing. Nucleic Acids Res. 2011, 39, e81. [CrossRef] [PubMed].
37. Hiatt, J. B.; Pritchard, C. C.; Salipante, S. J.; O'Roak, B. J.; Shendure, J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013, 23, 843-854. [CrossRef] [PubMed].
38. Islam, S.; Zeisel, A.; Joost, S.; La Manno, G.; Zajac, P.; Kasper, M.; Lonnerberg, P.; Linnarsson, S. Quantitative single-cell RNA-seq with unique molecular identifiers. Nat. Methods 2014, 11, 163-166. [CrossRef] [PubMed].
39. Hodges, E.; Xuan, Z.; Balija, V.; Kramer, M.; Molla, M. N.; Smith, S. W.; Middle, C. M.; Rodesch, M. J.; Albert, T. J.; Hannon, G. J.; et al. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 2007, 39, 1522-1527. [CrossRef] [PubMed].
40. Okou, D. T.; Steinberg, K. M.; Middle, C.; Cutler, D. J.; Albert, T. J.; Zwick, M. E. Microarray-based genomic selection for high-throughput resequencing. Nat. Methods 2007, 4, 907-909. [CrossRef] [PubMed].
41. Albert, T. J.; Molla, M. N.; Muzny, D. M.; Nazareth, L.; Wheeler, D.; Song, X.; Richmond, T. A.; Middle, C. M.; Rodesch, M. J.; Packard, C. J.; et al. Direct selection of human genomic loci by microarray hybridization. Nat. Methods 2007, 4, 903-905. [CrossRef] [PubMed].
42. Liu, B.; Morrison, C. D.; Johnson, C. S.; Trump, D. L.; Qin, M.; Conroy, J. C.; Wang, J.; Liu, S. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: Principles and challenges. Oncotarget 2013, 4, 1868-1881. [PubMed].
43. Zhao, M.; Wang, Q.; Wang, Q.; Jia, P.; Zhao, Z. Computational tools for copy number variation (cnv) detection using next-generation sequencing data: Features and perspectives. BMC Bioinformatics 2013, 14, S1. [CrossRef] [PubMed].
44. Fiorentino, F.; Biricik, A.; Bono, S.; Spizzichino, L.; Cotroneo, E.; Cottone, G.; Kokocinski, F.; Michel, C. E. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertil. Steril. 2014, 101, 1375-1382. [CrossRef] [PubMed].
45. Fiorentino, F.; Bono, S.; Biricik, A.; Nuccitelli, A.; Cotroneo, E.; Cottone, G.; Kokocinski, F.; Michel, C. E.; Minasi, M. G.; Greco, E. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Hum. Reprod. 2014, 29, 2802-2813. [CrossRef] [PubMed].
46. Pinkel, D.; Segraves, R.; Sudar, D.; Clark, S.; Poole, I.; Kowbel, D.; Collins, C.; Kuo, W. L.; Chen, C.; Zhai, Y.; et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998, 20, 207-211. [CrossRef] [PubMed].
47. Pollack, J. R.; Perou, C. M.; Alizadeh, A. A.; Eisen, M. B.; Pergamenschikov, A.; Williams, C. F.; Jeffrey, S. S.; Botstein, D.; Brown, P. O. Genome-wide analysis of DNA copy-number changes using cdna microarrays. Nat. Genet. 1999, 23, 41-46. [CrossRef] [PubMed].
48. Lo, J.; Kerns, B. J.; Amling, C. L.; Robertson, C. N.; Layfield, L. J. Correlation of DNA ploidy and histologic diagnosis from prostate core-needle biopsies: Is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? J. Surg. Oncol. 1996, 63, 41-45. [CrossRef].
49. Koivisto, P. Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostat. Dis. 1997, 1, 21-25. [CrossRef] [PubMed].
50. Reinholz, M. M.; Bruzek, A. K.; Visscher, D. W.; Lingle, W. L.; Schroeder, M. J.; Perez, E. A.; Jenkins, R. B. Breast cancer and aneusomy 17: Implications for carcinogenesis and therapeutic response. Lancet 2009, 10, 267-277. [CrossRef].
51. Krishnamurti, U.; Hammers, J. L.; Atem, F. D.; Storto, P. D.; Silverman, J. F. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod. Pathol. 2009, 22, 1044-1048. [CrossRef] [PubMed].
52. Watters, A. D.; Going, J. J.; Cooke, T. G.; Bartlett, J. M. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res. Treat. 2003, 77, 109-114. [CrossRef] [PubMed].
53. Hagenkord, J. M.; Chang, C. C. The rewards and challenges of array-based karyotyping for clinical oncology applications. Leukemia 2009, 23, 829-833. [CrossRef] [PubMed].
54. Gunn, S. R.; Mohammed, M. S.; Gorre, M. E.; Cotter, P. D.; Kim, J.; Bahler, D. W.; Preobrazhensky, S. N.; Higgins, R. A.; Bolla, A. R.; Ismail, S. H.; et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J. Mol. Diagn. 2008, 10, 442-451. [CrossRef] [PubMed].
55. Lyons-Weiler, M.; Hagenkord, J.; Sciulli, C.; Dhir, R.; Monzon, F. A. Optimization of the affymetrix genechip mapping 10k 2. 0 assay for routine clinical use on formalin-fixed paraffin-embedded tissues. Diagn. Mol. Pathol. 2008, 17, 3-13. [CrossRef] [PubMed].
56. Ciriello, G.; Miller, M. L.; Aksoy, B. A.; Senbabaoglu, Y.; Schultz, N.; Sander, C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45, 1127-1133. [CrossRef] [PubMed].
57. Paik, S.; Kim, C.; Wolmark, N. Her2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 2008, 358, 1409-1411. [CrossRef] [PubMed].
58. Wolff, A. C.; Hammond, M. E.; Hicks, D. G.; Dowsett, M.; McShane, L. M.; Allison, K. H.; Allred, D. C.; Bartlett, J. M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31, 3997-4013. [CrossRef] [PubMed].
59. Dowsett, M.; Hanna, W. M.; Kockx, M.; Penault-Llorca, F.; Ruschoff, J.; Gutjahr, T.; Habben, K.; van de Vijver, M. J. Standardization of her2 testing: Results of an international proficiency-testing ring study. Mod. Pathol. 2007, 20, 584-591. [CrossRef] [PubMed].
60. Gunn, S.; Yeh, I. T.; Lytvak, I.; Tirtorahardjo, B.; Dzidic, N.; Zadeh, S.; Kim, J.; McCaskill, C.; Lim, L.; Gorre, M.; et al. Clinical array-based karyotyping of breast cancer with equivocal her2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 2010, 10. [CrossRef] [PubMed].
61. Sapino, A.; Goia, M.; Recupero, D.; Marchio, C. Current challenges for her2 testing in diagnostic pathology: State of the art and controversial issues. Front. Oncol. 2013, 3, 129. [CrossRef] [PubMed].
62. Hansen, T. V.; Vikesaa, J.; Buhl, S. S.; Rossing, H. H.; Timmermans-Wielenga, V.; Nielsen, F. C. High-density snp arrays improve detection of her2 amplification and polyploidy in breast tumors. BMC Cancer 2015, 15. [CrossRef] [PubMed].
63. Gunn, S. R. The vanguard has arrived in the clinical laboratory: Array-based karyotyping for prognostic markers in chronic lymphocytic leukemia. J. Mol. Diagn. 2010, 12, 144-146. [CrossRef] [PubMed].
64. Wang, Y.; Carlton, V. E.; Karlin-Neumann, G.; Sapolsky, R.; Zhang, L.; Moorhead, M.; Wang, Z. C.; Richardson, A. L.; Warren, R.; Walther, A.; et al. High quality copy number and genotype data from ffpe samples using molecular inversion probe (mip) microarrays. BMC Med. Genom. 2009, 2. [CrossRef] [PubMed].
65. Wang, Q.; Jia, P.; Li, F.; Chen, H.; Ji, H.; Hucks, D.; Dahlman, K. B.; Pao, W.; Zhao, Z. Detecting somatic point mutations in cancer genome sequencing data: A comparison of mutation callers. Genome Med. 2013, 5. [CrossRef] [PubMed].
66. Stead, L. F.; Sutton, K. M.; Taylor, G. R.; Quirke, P.; Rabbitts, P. Accurately identifying low-allelic fraction variants in single samples with next-generation sequencing: Applications in tumor subclone resolution. Hum. Mutat. 2013, 34, 1432-1438. [CrossRef] [PubMed].
67. Koboldt, D. C.; Zhang, Q.; Larson, D. E.; Shen, D.; McLellan, M. D.; Lin, L.; Miller, C. A.; Mardis, E. R.; Ding, L.; Wilson, R. K. Varscan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012, 22, 568-576. [CrossRef] [PubMed].
68. Cibulskis, K.; Lawrence, M. S.; Carter, S. L.; Sivachenko, A.; Jaffe, D.; Sougnez, C.; Gabriel, S.; Meyerson, M.; Lander, E. S.; Getz, G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013, 31, 213-219. [CrossRef] [PubMed].
69. Karow, J. Tumor-only sequencing may misguide therapy but many labs omit matched control. Available online: https://www. genomeweb. com/cancer/tumor-only-sequencing-may-misguidetherapy-many-labs-omit-matched-control (accessed on 15 May 2015).
70. Jones, S.; Anagnostou, V.; Lytle, K.; Parpart-Li, S.; Nesselbush, M.; Riley, D. R.; Shukla, M.; Chesnick, B.; Kadan, M.; Papp, E.; et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 2015, 7, 283ra53. [CrossRef] [PubMed].
71. Hodgson, S. Mechanisms of inherited cancer susceptibility. J. Zhejiang Uni. Sci. B 2008, 9, 1-4. [CrossRef] [PubMed].
72. Parsons, D. W.; Roy, A.; Plon, S. E.; Roychowdhury, S.; Chinnaiyan, A. M. Clinical tumor sequencing: An incidental casualty of the american college of medical genetics and genomics recommendations for reporting of incidental findings. J. Clin. Oncol. 2014, 32, 2203-2205. [CrossRef] [PubMed].
73. Waddell, N.; Jonnalagadda, J.; Marsh, A.; Grist, S.; Jenkins, M.; Hobson, K.; Taylor, M.; Lindeman, G. J.; Tavtigian, S. V.; Suthers, G.; et al. Characterization of the breast cancer associated atm 7271T>G (V2424G) mutation by gene expression profiling. Genes Chromosom. Cancer 2006, 45, 1169-1181. [CrossRef] [PubMed].
74. Stankovic, T.; Kidd, A. M.; Sutcliffe, A.; McGuire, G. M.; Robinson, P.; Weber, P.; Bedenham, T.; Bradwell, A. R.; Easton, D. F.; Lennox, G. G.; et al. Atm mutations and phenotypes in ataxia-telangiectasia families in the british isles: Expression of mutant atm and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet. 1998, 62, 334-345. [CrossRef] [PubMed].
75. Bernstein, J. L.; Teraoka, S.; Southey, M. C.; Jenkins, M. A.; Andrulis, I. L.; Knight, J. A.; John, E. M.; Lapinski, R.; Wolitzer, A. L.; Whittemore, A. S.; et al. Population-based estimates of breast cancer risks associated with atm gene variants c. 7271t>g and c. 1066-6t>g (ivs10-6t>g) from the breast cancer family registry. Hum. Mutat. 2006, 27, 1122-1128. [CrossRef] [PubMed].
76. Goldgar, D. E.; Healey, S.; Dowty, J. G.; Da Silva, L.; Chen, X.; Spurdle, A. B.; Terry, M. B.; Daly, M. J.; Buys, S. M.; Southey, M. C.; et al. Rare variants in the atm gene and risk of breast cancer. Breast Cancer Res. 2011, 13, R73. [CrossRef] [PubMed].
77. Abraham, R. T. Cell cycle checkpoint signaling through the atm and atr kinases. Genes Dev. 2001, 15, 2177-2196. [CrossRef] [PubMed].
78. Lavin, M. F. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 2008, 9, 759-769. [CrossRef] [PubMed].
79. Kitagawa, R.; Kastan, M. B. The ATM-dependent DNA damage signaling pathway. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 99-109. [CrossRef] [PubMed].
80. Yelamos, J.; Farres, J.; Llacuna, L.; Ampurdanes, C.; Martin-Caballero, J. Parp-1 and parp-2: New players in tumour development. Am. J. Cancer Res. 2011, 1, 328-346. [PubMed].
81. Tangutoori, S.; Baldwin, P.; Sridhar, S. Parp inhibitors: A new era of targeted therapy. Maturitas 2015, 81, 5-9. [CrossRef] [PubMed].
82. Wang, Y.; Cottman, M.; Schiffman, J. D. Molecular inversion probes: A novel microarray technology and its application in cancer research. Cancer Genet. 2012, 205, 34-55. [CrossRef] [PubMed].
83. Piha-Paul, S. Phase II study of BMN 673. Available online: https://clinicaltrials. gov/ct2/show/NCT02286687 (accessed on 15 May 2015).
84. FDA approves lynparza to treat advanced ovarian cancer. Available online: http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554. htm (accessed on 15 May 2015).